The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma Summary CAR-T cell therapy for multiple myeloma significantly alters the patient’s existing T cell population. This Read More
Tags :Myeloma
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma Summary Plasmapheresis, a procedure that filters blood, has shown promise in overcoming resistance to anti-BCMA immunotherapies for multiple Read More
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Summary Daratumumab refractoriness significantly worsens outcomes after CAR T-cell therapy in patients with relapsed/refractory multiple myeloma. Studies show Read More
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management-
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series Summary This case series highlights a newly recognized side effect of talquetamab, a GPRC5D-targeting bispecific antibody used to treat multiple Read More
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma Summary Real-world data on idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapy for multiple Read More